作者采用前瞻性随机双盲对照方法评估了重组人类粒细胞集落刺激因子(G-CSF)治疗经一个标准疗程的加强化疗后复发或难治性急性白血病的安全性和疗效。 108例患者,其中急性髓性白血病67例,急性淋巴性白血病30例、慢性髓性白血病原始细胞危象9例和由骨髓增生异常综合征引起的急性白血病2例。方法:所有病人接受氨甲喋呤(5mg/m~2/日,静滴,第1～3天)、鬼臼乙又甙(80mg/m~2/日,静滴,第1～5天)和阿糖山芋酰胞苷(enocitabine,170mg/m~2/ The authors evaluated the safety and efficacy of recombinant human granulocyte colony-stimulating factor (G-CSF) in the treatment of relapsed or refractory acute leukemia after a standard course of enhanced chemotherapy, using a prospective, randomized, double-blind, controlled study. Of the 108 patients, 67 were acute myeloid leukemia, 30 were acute lymphoblastic leukemia, 9 were primary cell crisis of chronic myelogenous leukemia, and 2 were acute leukemia caused by myelodysplastic syndrome. METHODS: All patients received methotrexate (5 mg/m 2/day, intravenous infusion, 1st to 3rd days), guifei yiyou (80mg/m~2/day, intravenous infusion, 1st to 5th days) and Sugar cytidine (enocitabine, 170mg/m~2/